OphthaliX, Inc. is a clinical stage biopharmaceutical company focused on developing therapeutic products for the treatment of ophthalmic disorders. Its drug candidate, CF101, is a novel first in class small molecule orally bioavailable drug, which is being developed to treat three ophthalmic indications: dry eye syndrome; glaucoma and uveitis. The company was founded on December 10, 1999 and is headquartered in Carson City, NV.

